Viking Therapeutics Inc - ESG Rating & Company Profile powered by AI
The page includes a Q&A table on Viking Therapeutics Inc. Complete Sustainability analysis of Viking Therapeutics Inc can be accessed by registering for free. Jump to the bottom of the webpage for potential risks for Viking Therapeutics Inc based on industry, geography and size.
Viking Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.1; made up of an environmental score of 4.8, social score of 3.2 and governance score of 4.0.
4.1
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 1376 | Vericel Corp | 4.2 | High |
| 1376 | vTv Therapeutics Inc | 4.2 | High |
| 1412 | Viking Therapeutics Inc | 4.1 | High |
| 1412 | Abivax SA | 4.1 | High |
| 1412 | Aeglea Bio Therapeutics Inc | 4.1 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Viking Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Viking Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Viking Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Viking Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Viking Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Viking Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Viking Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Viking Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Viking Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Viking Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Viking Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Viking Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Viking Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Viking Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Viking Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Viking Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Viking Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Viking Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.